This plot summarizes the available laboratory evidence on the ability of COVID-19 vaccines to neutralize SARS-CoV-2 variants of concern.

These forest plots summarize available COVID-19 vaccine effectiveness against Omicron variant by vaccine and population of special interest, and for second booster dose and duration of effectiveness. These forest plots are updated regularly.

Filterable spreadsheets of vaccine effectiveness studies included in the weekly summary tables. Separate spreadsheets are available for primary series and booster dose studies.

This table summarizes the vaccine effectiveness data for COVID-19 studies conducted globally. This table is updated weekly. 

The VIEW-hub Report captures changes in introduction status and use for the vaccines monitored on VIEW-hub made between September 1–December 31, 2024.

The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.

This checklist, intended for researchers, aims to improve comparability, consistency and reliability across SARS-CoV-2 neutralization studies thereby increasing utility for vaccine decision-making.

The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Hib, and inactivated polio vaccines both globally and in the 54 Gavi countries.

This document outlines the methods used in the COVID-19 vaccines effectiveness and impact studies review. 

The Vaccine Economics Research for Sustainability and Equity (VERSE) project evaluated the status of vaccine coverage and equity status in the Democratic Republic of the Congo in 2013. Note: This resource is in French.